Use of Dolutegravir to Treat People Living With HTLV-1–associated Myelopathy (HAM)
Clinical Infectious Diseases · 21.05.2026
DOI: 10.1093/cid/ciag323 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 21.05.2026. Verfasst von Jorge Casseb und 2 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Dermatologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. Die Arbeit nennt 7 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Departamento de Dermatologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
- Departamento de Medicina Legal, Bioética, Medicina do Trabalho e Medicina Física e Reabilitação, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
- Instituto de Infectologia Emilio Ribas, Secretaria de Saúde do Estado de São Paulo, São Paulo, Brazil.
ORCID-Profile: Jorge Casseb
Zitieren
APA
Casseb, J., Assone, T., & de Oliveira, A. C. P. (2026). Use of Dolutegravir to Treat People Living With HTLV-1–associated Myelopathy (HAM). Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag323
Vancouver
Casseb J, Assone T, de Oliveira ACP. Use of Dolutegravir to Treat People Living With HTLV-1–associated Myelopathy (HAM). Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag323
BibTeX
@article{Casseb2026,
author = {Casseb, Jorge and Assone, Tatiane and de Oliveira, Augusto César Penalva},
title = {Use of Dolutegravir to Treat People Living With HTLV-1–associated Myelopathy (HAM)},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciag323}
}
EUVIMED